|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Lung ultrasound (LUS) has also been shown to be more accurate than chest x-ray in identifying pulmonary consolidation and pulmonary edema, both of which are found in patients with COVID. The investigators hypothesize implementation of LUS by hospitalists in the management of suspected or diagnosed patients with COVID-19 will reduce the need for Chest CT and chest x-ray, thereby conserving PPE, reducing risk of transmission to technicians and conserving the resources of radiology services that would otherwise be overwhelmed by patients with COVID-19 in need of chest imaging. Using the methods of implementation science, the investigators propose to respond to the urgent need for rapid implementation of LUS by hospitalists in management of adult patients hospitalized for COVID. Aim 1a: Using a rapid-cycle weekly Plan-Do-Study-Act cycle and Rapid Iterative RE-AIM, to optimize the implementation of LUS by adult hospitalists in the management of COVID-19 patients in a pilot study Aim 1b: Evaluate this pilot implementation of LUS by adult hospitalists using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework.
Description: number of hospitalists who obtain lung ultrasound in their patients with COVIDMeasure: Adoption of lung ultrasound by hospitalists caring for patients with COVID Time: 1 year
Description: percentage of patients with COVID who receive a lung ultrasoundMeasure: Percentage of patients with COVID who receive a lung ultrasound Time: 1 year
Description: Compare number of chest x-rays obtained in patients with COVID prior to lung ultrasound implementation intervention versus afterMeasure: Chest x-ray utilization Time: 1 year
Description: Expert adjudication of the adequacy of images, interpretation and clinical decision-making using lung ultrasoundMeasure: Adequacy of Lung ultrasound images, interpretation and clinical decision-making as measured by a lung ultrasound expert Time: 1 year
Description: Compare inpatient mortality of patients with COVID prior to lung ultrasound implementation versus after adjusted for risk factorsMeasure: Inpatient mortality Time: 1 year
Description: Feasibility of using lung ultrasound as measured by a validated survey completed by hospitalistsMeasure: Lung ultrasound Feasibility score Time: 1 year
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports